Market Research Logo

Global peptic ulcer drugs market 2017-2021

Global peptic ulcer drugs market 2017-2021

About Peptic Ulcer Drugs

A peptic ulcer is an open lesion, which develops on the mucosal lining of the stomach and the small intestine due to the caustic effect of the gastric acid and pepsin present in these organs. The general symptoms of a peptic ulcer include abdominal pain, nausea, vomiting, and bloated stomach. The specific symptom of peptic ulcer is the bleeding of the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. It is caused mainly by the Helicobacter pylori bacteria followed by the overuse of over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen, aspirin, and ibuprofen.

Technavio’s analysts forecast the global peptic ulcer drugs market to grow at a CAGR of 2.80% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global peptic ulcer drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Peptic Ulcer Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca,
  • Daewoong Pharmaceuticals,
  • Eisai,
  • Takeda Pharmaceutical
Other prominent vendors
  • GlaxoSmithKline
  • Pfizer
Market driver
  • Economics of treating ulcer
  • For a full, detailed list, view our report
Market challenge
  • Adverse effect of PPIs
  • For a full, detailed list, view our report
Market trend
  • Bismuth-based quadruple therapy
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Peptic Ulcer Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global peptic ulcer drugs market: AstraZeneca, Daewoong Pharmaceuticals, Eisai, and Takeda Pharmaceutical.

Other Prominent Vendors in the market are: GlaxoSmithKline and Pfizer.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Bismuth-based quadruple therapy. Bismuth-based quadruple therapy has emerged as an alternative therapy to address the demand for anti-resistant drugs for the treatment of peptic ulcer. The traditional treatment regimen for peptic ulcer involves the use of clarithromycin or levofloxacin-based triple therapy, which became resistant to H. pylori bacteria, thus leaving most individuals untreated. To offset the impact of antibiotic resistance, the modern therapeutic approach for the treatment of peptic ulcer is based on bismuth-based quadruple therapy, which involves the use of drugs, such as bismuth salt, tetracycline, and metronidazole, for which antibiotic resistance is rarely encountered.”

According to the report, one of the major drivers for this market is economics of treating ulcer. The under use of antibiotic therapy for the treatment of peptic ulcer associated with H. pylori infection not only leads to unnecessary loss of productivity but also causes enormous economic loss to the individual. As per a CDC report, approximately 10%-15% of peptic ulcer adults living in the US are in poor health condition and unable to perform routine activities.

Further, the report states that one of the major factors hindering the growth of this market is Adverse effect of PPIs. As per the US FDA, the use of PPIs for acid suppression in peptic ulcer patients is associated with an increased risk of CDAD. C. difficile is a bacterium, which causes diarrhea that does not improve over time. Its symptoms include watery stools, abdominal pain, fever, and may even lead to severe intestinal conditions. CDAD causes loss of vital nutrients from the body, and its treatment involves administration of fluids rich in nutrients and electrolyte in combination with antibiotics. The US FDA recommends CDAD diagnosis for patients with diarrhea that does not improve over time.

Companies Mentioned

AstraZeneca, Daewoong Pharmaceuticals, Eisai, and Takeda Pharmaceutical.GlaxoSmithKline and Pfizer.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Types of peptic ulcer
  • Peptic ulcers: Disease overview
  • Key clinical trials
    • Table Global peptic ulcer drugs market: Pipeline landscape based on sponsors
    • Table Global peptic ulcer drugs market: Pipeline landscape
    • Table Global peptic ulcer drugs market: List of clinical trials and their aim/purpose
  • Market landscape
    • Market overview
      • Table Snapshot of global peptic ulcer drugs market
    • Market size and forecast
      • Table Global peptic ulcer drugs market 2016-2021 ($ millions)
      • Table Opportunity analysis in global peptic ulcer drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Segmentation of global peptic ulcer drugs market based on drug class 2016
    • Table Global peptic ulcer drugs market share based on drug class 2016
    • PPIs
      • Table Global peptic ulcer PPIs drugs market 2016-2021 ($ millions)
    • Antibiotics
      • Table Global peptic ulcer antibiotics drugs market 2016-2021 ($ millions)
    • Others
      • Table Global peptic ulcer drugs market for others 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Segmentation of global peptic ulcer drugs market based on geography 2016 and 2021
    • Table Segmentation of global peptic ulcer drugs market revenue based on geography 2016-2021
    • Table Segmentation of global peptic ulcer drugs market based on geography 2016-2021 (%)
    • Peptic ulcer drugs market in Americas
      • Table Market scenario in Americas
      • Table Peptic ulcer drugs market in Americas 2016-2021 ($ millions)
    • Peptic ulcer drugs market in EMEA
      • Table Market scenario in EMEA
      • Table Peptic ulcer drugs market in EMEA 2016-2021 ($ millions)
    • Peptic ulcer drugs market in APAC
      • Table Market scenario in APAC
      • Table Peptic ulcer drugs market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Age-related proportion of patients with duodenal and gastric ulcer
      • Table Some of the marketed combination products
    • Market challenges
      • Table Revenue erosion of Pariet after loss of exclusivity
  • Market trends
    • Bismuth-based quadruple therapy
    • Emergence of monotherapy
    • Recurrent H. pylori infections
    • Rise in awareness
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global peptic ulcer drugs market 2016
  • Key vendor analysis
    • AstraZeneca
      • Table AstraZeneca: Key highlights
      • Table AstraZeneca: Strength assessment
      • Table AstraZeneca: Strategy assessment
      • Table AstraZeneca: Opportunity assessment
    • Daewoong Pharmaceuticals
      • Table Daewoong Pharmaceuticals: Key highlights
      • Table Daewoong Pharmaceuticals: Strength assessment
      • Table Daewoong Pharmaceuticals: Strategy assessment
      • Table Daewoong Pharmaceuticals: Opportunity assessment
    • Eisai
      • Table Eisai: Key highlights
      • Table Eisai: Strength assessment
      • Table Eisai: Strategy assessment
      • Table Eisai: Opportunity assessment
    • Takeda Pharmaceutical
      • Table Takeda Pharmaceutical: Key highlights
      • Table Takeda Pharmaceutical: Strength assessment
      • Table Takeda Pharmaceutical: Strategy assessment
      • Table Takeda Pharmaceutical: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report